Siemens Healthineers meets annual revenue and profit view, shares jump 8%
Adds China context, details and quotes from analyst presentation in paragraphs 4-10
By Marleen Kaesebier and Jörn Poltz
Nov 6 (Reuters) -Siemens Healthineers SHLG.DE met its annual revenue and profit growth forecast on Wednesday, as strength in its Imaging segment and U.S. cancer treatment unit Varian in the fourth quarter outweighed weakness in China, sending its shares up 8.1%.
The German medical technology company's comparable revenue growth was at 4.7% for the year ended Sept. 30, slightly missing analysts' forecast of 4.8%, according to a Vara Research-compiled consensus. It was at the lower end of the company's 4.5%-6.5% estimate.
Adjusted earnings before interest and taxes (EBIT) at 3.5 billion euros ($3.77 billion) also met analysts' estimates.
In China, revenue declined by a mid-single-digit percentage in the fourth quarter on currently delayed customer orders, the company said, but it sees "very strong" comparable revenue growth in the Americas.
Last week, rival medical devices maker Philips PHG.AS cut its 2024 sales outlook after flagging that demand for its products in China was hit by deteriorating consumer confidence in the country and the ongoing state-led anti-corruption campaign, which led to Chinese hospitals cutting back orders.
"We assume China revenue in the first half of fiscal year 2025 to decline mid-single-digit to high-single-digit percentage points," Siemens Healthineers CFO Jochen Schmitz said in a press briefing.
"In the second half of 2025, we assume revenue to be roughly at the level of the second half of fiscal 2024."
CEO Bernd Montag reiterated that the management believes China will stay attractive in the mid- and long-term.
The company expects a 5%-6% comparable revenue growth in 2025 and the adjusted basic earnings per share to be between 2.35 euros and 2.50 euros.
It also confirmed mid-term targets beyond 2025 and said it expects high-single-digits 2025 revenue growth in its Varian segment and a "mid-single-digits" revenue growth in Imaging, after the latter grew 7.7% in the fourth quarter, largely beating analyst expectations of 6.7%.
($1 = 0.9294 euros)
Reporting by Marleen Kaesebier and Joern Plotz; Editing by Sumana Nandy and Rashmi Aich
Aloqador aktivlar
Eng oxirgi yangiliklar
Javobgarlikdan voz kechish: XM Group korxonalari har biri faqat ijro xizmatlarini koʻrsatadi va onlayn savdo platformamizdan foydalanish huquqini beradi, bu odamga veb-saytda yoki veb-sayt orqali mavjud boʻlgan kontentni koʻrish va/yoki undan foydalanishga ruxsat beradi hamda uni oʻzgartirishga moʻljallanmagan va uni oʻzgartirmaydi yoki kengaytirmaydi. Bunday kirish va foydalanish huquqi doimo quyidagilarga boʻysunadi: (i) Shartlar va qoidalar; (ii) Risklar haqida ogohlantirish; va (iii) Javobgarlikni toʻliq rad etish. Shuning uchun bunday kontent umumiy maʼlumot sifatida taqdim etiladi. Xususan, shuni esda tutingki, bizning onlayn savdo platformamiz mazmuni moliyaviy bozorlarda biror bitimni amalga oshirishga oid maslahat yoki taklif emas. Har qanday moliyaviy bozorda savdo qilish sizning kapitalingiz uchun jiddiy risk darajasini oʻz ichiga oladi.
Onlayn savdo platformamizda chop etilgan barcha materiallar faqat taʼlim/axborot maqsadlari uchun moʻljallangan va unda moliyaviy, investitsiya soligʻi yoki savdo maslahatlari va tavsiyalar; yoki bizning savdo narxlarimizning qaydlari; yoki har qanday moliyaviy vositalar bilan bitim tuzish maslahati yoki taklifi; yoki sizga kerak boʻlmagan moliyaviy reklama aksiyalari hisoblanmaydi
Har qanday uchinchi tomon kontenti, shuningdek XM tomonidan tayyorlangan kontent, masalan: fikrlar, yangiliklar, tadqiqotlar, tahlillar, narxlar va boshqa maʼlumotlar yoki bu veb-saytda joylashgan uchinchi tomon saytlariga havolalar umumiy bozor sharhi sifatida "boricha" taqdim etiladi va investitsiya maslahatini tashkil etmaydi. Har qanday kontent investitsiya tadqiqoti sifatida talqin qilinsa, siz bunday kontentni investitsiya tadqiqotlarining mustaqilligini ragʻbatlantirish uchun moʻljallangan qonun talablariga muvofiq moʻljallanmagan va tayyorlanmaganligini eʼtiborga olishingiz va qabul qilishingiz kerak, shuning uchun unga tegishli qonunlar va qoidalarga muvofiq marketing kommunikatsiyasi sifatida qaraladi. Mustaqil boʻlmagan investitsiya tadqiqoti va yuqoridagi maʼlumotlarga oid risk haqida ogohlantirishimizni oʻqib chiqqaningizga va tushunganingizga ishonch hosil qiling, unga bu yerdan kirish mumkin.
